Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.50 |
| ▸ | WNT3A | P56704 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12536449 | 0.83 | MAPT (0.57) | MAPTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL138885 | 0.82 | IDO1 (0.50) | MAPTKMT2AMEN1NPC1L3MBTL1 | |
| SCHEMBL395494 | 0.81 | MAPT (0.56) | MAPTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL28573906 | 0.81 | SMN1; SMN2 (0.51) | MAPTKMT2AMEN1NPC1HTT | |
| SCHEMBL5675350 | 0.81 | HPGDS (0.66) | MAPTKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL12536506 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL17380989 | 0.80 | MAPT (0.78) | MAPTKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL21128714 | 0.80 | NPC1 (0.83) | MAPTKMT2AMEN1NPC1CTSD | |
| SCHEMBL29987209 | 0.80 | NPC1 (0.83) | MAPTKMT2AMEN1NPC1CTSD | |
| SCHEMBL15979734 | 0.80 | CTNNB1 (0.71) | KMT2ANPC1CTSDL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK A/S (DK) | 2025-05-08 | — | — | US | disclosed |
| WO-2025064210-A1 | INHIBITORS OF BILIVERDIN REDUCTASE B (BLVRB) | BLOOD CELL TECHNOLOGIES, LLC (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119301126-A | Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound | 诺和诺德股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119192171-A | Small molecule compounds and their use in vitro expansion of hematopoietic stem cells and/or progenitor cells | 上海交通大学医学院 | 2024-12-27 | — | — | CN | disclosed |
| EP-4479402-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-12-25 | — | — | EP | disclosed |
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| CN-117624188-A | Cyclopentathiofuran carboxamide derivatives as platelet-activating factor receptor antagonists | 勃林格殷格翰国际有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-4728743-A | Process for the production of 3-oxonitriles | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | disclosed |
| US-4716237-A | Process for the production of 3-oxonitriles | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-12-29 | — | — | US | disclosed |
| EP-0089011-B1 | PROCESS FOR THE PREPARATION OF 5-OXONITRILES | Degussa Aktiengesellschaft (DE) | 1985-07-10 | — | — | EP | disclosed |
| EP-0089011-A1 | Process for the preparation of 5-oxonitriles | Degussa Aktiengesellschaft (DE) | 1983-09-21 | — | — | EP | disclosed |
| EP-0016277-B1 | 2-CARBONYL-3-HYDROXY-ALKENONITRILES, THEIR USE AS ANTI-ARTHRITIC AGENTS AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| US-4259256-A | ANTIINFLAMMATORY | AMERICAN CYANAMID COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4181677-A | ANTIINFLAMMATORY AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | MAPT 1141/4885KMT2A 4313/4885MEN1 107/4885 |
| US-20250145628-A1 | PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, TRPV1 | MAPT 74/4885KMT2A 3336/4885MEN1 2114/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | MAPT 1236/4885KMT2A 4080/4885MEN1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.